JOHNSON CHEMICAL PHARMACEUTICAL WORKS CO., LTD. Johnson Chemical Pharmaceutical Works Co., Ltd. Share Price
Equities
4747
TW0004747001
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.8 TWD | +3.51% |
|
+1.00% | -15.41% |
| Sales 2022 | 495M 15.27M 1.27B | Sales 2023 | 607M 18.72M 1.56B | Capitalization | 3.66B 113M 9.42B |
|---|---|---|---|---|---|
| Net income 2022 | 64M 1.98M 165M | Net income 2023 | 79M 2.44M 204M | EV / Sales 2022 | 2.89 x |
| Net cash position 2022 | 108M 3.35M 280M | Net cash position 2023 | 927M 28.6M 2.39B | EV / Sales 2023 | 4.5 x |
| P/E ratio 2022 |
23.7
x | P/E ratio 2023 |
38.4
x | Employees | 172 |
| Yield 2022 |
3.91% | Yield 2023 |
1.79% | Free-Float | 69.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.51% | ||
| 1 week | +1.00% | ||
| Current month | +1.00% | ||
| 1 month | -4.07% | ||
| 3 months | -12.59% | ||
| 6 months | -18.24% | ||
| Current year | -15.41% |
1 week
68.20
70.80
1 month
68.2077.50
Current year
63.0091.60
1 year
63.00122.50
3 years
30.05122.50
5 years
30.05122.50
10 years
30.05122.50
| Managers | Title | Age | Since |
|---|---|---|---|
Pai Hsiung Huang
CEO | Chief Executive Officer | - | 14/92/14 |
I Hsiu Chen
DFI | Director of Finance/CFO | - | - |
Pai Shou Huang
BRD | Director/Board Member | - | 24/13/24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pai Hsiung Huang
CEO | Chief Executive Officer | - | 14/92/14 |
Pai Hsun Huang
BRD | Director/Board Member | - | 02/07/02 |
Kuo An Liao
BRD | Director/Board Member | - | 30/95/30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/24/07 | 70.8 | +3.51% | 128,688 |
| 06/24/06 | 68.4 | -0.15% | 45,793 |
| 05/24/05 | 68.5 | -1.01% | 73,285 |
| 04/24/04 | 69.2 | -0.86% | 61,179 |
| 03/24/03 | 69.8 | -0.43% | 37,577 |
End-of-day quote Taipei Exchange, June 07, 2024
More quotes
Johnson Chemical Pharmaceutical Works Co., Ltd. is a Taiwan-based company principally engaged in the manufacture and distribution of western medicines and the related raw materials. The Company mainly provides solid dosage forms, including soft and hard capsules, sugar coated tablets, film-coated tablets, suppositories, powder, granules, tablets and others. The Companyâs products include central nervous system drugs, hormones and hormone function medicines, respiratory medicines, gastrointestinal drugs, vitamins and others. The Company mainly distributes its products in Taiwan market and the rest of Asia.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -15.41% | 98.06M | |
| +45.82% | 765B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B |
- Stock Market
- Equities
- 4747 Stock
